SIGN UP FOR UPDATES!
Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
ENGLEMED
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BOOKS AND GIFTS THIS WAY!
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here
SEARCH THIS SITE
Google

WWW Englemed
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
FreeDigitalPhotos
www.freedigitalphotos.net
FreeWebPhotos
www.freewebphoto.com
FROM OUR NEWS FEEDS
Heart failure ranked 'less important than potholes'
Tues June 28th - Heart failure is deemed less important than potholes in roads and pavements in the UK, according to an analysis published today. More
Cannabis users' increased risk of hospital admission
Tues June 28th - Canadian researchers have called for curbs on the globally rising levels of recreational cannabis because users have an increased risk of needing emergency care and hospital admission for any cause. More
RECENT COMMENTS
On 09/10/2020 William Haworth wrote:
How long is recovery time after proceedure... on Ablation cuts atrial fibrillat...
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote:
https://epidemicj17.imascientist.org.uk/2017/06/21... on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...
OUR CLIENTS
THIS WEEK'S STORIES
ENGLEMED HEALTH NEWS

Immunocompromised patients should have third COVID-19 vaccine

Thursday March 3rd 2022

Immunocompromised patients, particularly those who have had organ transplants, should receive additional COVID-19 vaccines, experts recommend today.

The findings, published in the latest edition of The BMJ, reinforce the importance of additional doses of COVID-19 vaccine to protect people with a weakened immune system.

Although it is known that immunocompromised people are less able to make antibodies after vaccination to fight off viruses, such as influenza, than those who are immunocompetent, less is known about the response to COVID-19 vaccines, particularly mRNA vaccines.

Researchers in Singapore analysed the results of 82 observational studies, to compare the effectiveness of COVID-19 vaccines in immunocompromised and immunocompetent people.

Of these studies, 77 (94%) used mRNA vaccines, 16 (20%) viral vector vaccines, and 4 (5%) inactivated whole virus vaccines. A total of 63 studies were assessed to be at low risk of bias and 19 at moderate risk of bias.

After one COVID-19 vaccine dose, seroconversion was found to be reduced among immunocompromised groups, except people with HIV.

Seroconversion rates were about half as likely in patients with blood cancers, immune mediated inflammatory disorders such as rheumatoid arthritis and psoriasis and solid cancers compared with immunocompetent controls. Organ transplant recipients were 16 times less likely to seroconvert.

A second dose significantly increased seroconversion in patients with blood cancers, immune mediated inflammatory disorders and solid cancers. However, only one third of transplant patients achieved seroconversion.

A further review of 11 studies showed that a third dose of a COVID-19 mRNA vaccine was associated with seroconversion among vaccine non-responders with solid cancers, blood cancers, and immune mediated inflammatory disorders. However, results showed a varied response in transplant recipients. No published evidence was available for people with HIV.

Although the included studies were observational and used different definitions of seroconversion, the research team said stringent study inclusion criteria, as well as rigorous and systematic evaluation of study quality, mean their conclusions are robust.

Lee Yan Bin AR, Wong SY, Chai LYA et al. Efficacy of COVID-19 vaccines in immunocompromised patients: systematic review and meta-analysis. BMJ 3 March 2022

[abstract]

Tags: Asia | Flu & Viruses | Pharmaceuticals | World Health

Printer friendly page Printer friendly page

Comment on this article:

Name:
Email:
Comment:
<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)
CATEGORIES